Eikonizo Therapeutics

Eikonizo Therapeutics is a biopharmaceutical company developing disease-modifying therapies for neurodegenerative and cardiorenal diseases. Their lead candidate, EKZ-102, is a first-in-class, oral HDAC6 inhibitor designed to protect neuronal function while minimizing side effects. The company aims to provide novel treatments targeting key drivers of these diseases.

Buy Funded Startups lists

Funding Round: Equity

Funding Amount:

Date: 10-Dec-2024

Investors: Novo Nordisk

Markets: Biopharmaceuticals, Neurodegenerative Diseases, Cardiorenal Diseases

HQ: Cambridge, Massachusetts, United States

Founded: 2017

Website: https://eikonizo.com/

LinkedIn: https://www.linkedin.com/company/eikonizo-therapeutics

Twitter: https://twitter.com/Eikonizo

Instagram: